Stay updated on Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial

Sign up to get notified when there's something new on the Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The site footer’s revision label updates from v3.7.2 to v3.8.0, while the clinical trial record and its version history remain unchanged.
    Difference
    0.0%
    Check dated 2026-11-03T23:35:47.000Z thumbnail image
  2. Check
    14 days ago
    No Change Detected
  3. Check
    21 days ago
    Change Detected
    Summary
    A site-wide notice was added about NIH’s transition from “Artificial Intelligence” to “Super Intelligence,” and the site revision number changed from v3.7.1 to v3.7.2.
    Difference
    0.3%
    Check dated 2026-10-20T23:28:12.000Z thumbnail image
  4. Check
    35 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov site revision number changed from v3.7.0 to v3.7.1.
    Difference
    0.0%
    Check dated 2026-10-07T00:07:24.000Z thumbnail image
  5. Check
    56 days ago
    Change Detected
    Summary
    The history now shows a new revision entry (v3.7.0) representing the latest update to the study record. The previous revision (v3.6.6) is no longer listed in the current version history.
    Difference
    0.0%
    Check dated 2026-09-15T23:34:19.000Z thumbnail image
  6. Check
    70 days ago
    Change Detected
    Summary
    A new revision entry 'Revision: v3.6.6' was added to the history, signaling an update to the record; the previous 'Revision: v3.6.5' entry was noted as removed in the change set.
    Difference
    0.0%
    Check dated 2026-09-01T19:02:59.000Z thumbnail image
  7. Check
    91 days ago
    Change Detected
    Summary
    The page shows the revision label updated from v3.6.4 to v3.6.5, indicating a new version of the study history interface.
    Difference
    0.0%
    Check dated 2026-08-11T19:21:08.000Z thumbnail image

Stay in the know with updates to Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial page.